NEW ORLEANS -- C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated therapy that rapidly relieves acute swelling attacks and successive attacks at any body location in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to data presented

read more>>

CAMBRIDGE, Mass. -- Dyax Corp. (NASDAQ:DYAX) announced today that KALBITOR(R) (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older is now commercially available in the United StatesHAE is a rare, genetic disorder characterized by sev

read more>>

KING OF PRUSSIA, Pa. -- CSL Behring announced today the launch of the Berinert® Expert Network (B.E.N.™), a full-service support program for healthcare providers and for hereditary angioedema (HAE) patients and their caregiversHAE is a rare and serious disorder that causes swelling in va

read more>>

CAMBRIDGE, Mass. -- A new, online resource is now available for patients with hereditary angioedema (HAE), their caregivers and physiciansThe website, www.HAEHope.com, launched today by Dyax Corp. (NASDAQ: DYAX), offers resources to help patients and their families better understand and manage HAE

read more>>

EXTON, Pa. -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that it has signed an agreement with Sanquin Blood Supply Foundation for rights to develop, file regulatory dossiers, and commercialize Cinryze(TM) (C1 esterase inhibitor [human]) for hereditary angioedema (HAE) as well as for Th

read more>>

EXTON, Pa. -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will provide an overview of the company's business and present a financial update during the 28th Annual J.P. Morgan Healthcare ConferenceAs previously ann

read more>>

EXTON, Pa. -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that it has signed an agreement with Sanquin Blood Supply Foundation for rights to develop, file regulatory dossiers, and commercialize Cinryze(TM) (C1 esterase inhibitor [human]) for hereditary angioedema (HAE) as well as for Th

read more>>

VOORHEES, N.J. -- Hereditary angioedema (HAE) is a disease affecting between 4,000 and 10,000 people in the United States each year, causing recurrent attacks of intense localized edemaHAE can be both difficult to diagnose and difficult to treat. Symptoms of HAE can resemble other more common cond

read more>>

Leiden, The Netherlands -- Biotech company Pharming Group NV (“Pharming”) (NYSE Euronext: PHARM) today confirmed its interactions in a pre-BLA meeting with the US Food and Drug Administration (FDA) on a proposed marketing application (BLA or Biologics License Application) to obtain In

read more>>

VOORHEES, N.J. - Hereditary angioedema (HAE) is an autosomal dominant disease estimated to afflict between 1 in 10,000 to 1 in 50,000 people in the United States.Patients with HAE suffer from recurrent attacks of intense localized edema involving the skin, airway, extremities, and visceral organs. Management of HAE may involve short-term treatment and long-term prophylaxis. There are currently…

read more>>